{"DataElement":{"publicId":"4199908","version":"1","preferredName":"Lung Cancer Systemic Therapy Administered Name","preferredDefinition":"The name of the systemic therapy administered to a patient with lung cancer.","longName":"LUNGSYSTX","context":"Alliance","contextVersion":"1","DataElementConcept":{"publicId":"2014193","version":"1","preferredName":"Systemic Therapy Administered","preferredDefinition":"the administration of systemic therapy to an individual.","longName":"SYSTX_ADM","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2176918","version":"1","preferredName":"Systemic Therapy","preferredDefinition":"(sis-TEM-ik THER-a-pee) Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.","longName":"Systemic Therapy","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Systemic Therapy","conceptCode":"C15698","definition":"Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"ACAAECCE-7AF4-657B-E034-0003BA0B1A09","latestVersionIndicator":"Yes","beginDate":"2002-10-29","endDate":null,"createdBy":"SBREXT","dateCreated":"2002-10-29","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2177665","version":"1","preferredName":"Administered","preferredDefinition":"Given.","longName":"Administered","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AE29A78C-516D-3A05-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-10-29","endDate":null,"createdBy":"SBREXT","dateCreated":"2002-10-29","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B5ECCD8F-CB00-09C1-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-02-05","endDate":null,"createdBy":"MWHITE","dateCreated":"2003-02-05","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"4199897","version":"1","preferredName":"Lung Cancer Systemic Therapy Administered Name","preferredDefinition":"The words or language units by which a thing is known.","longName":"LUNGSYSTX","context":"CTEP","contextVersion":"2.31","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"200","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Other","valueDescription":"Other","ValueMeaning":{"publicId":"2946060","version":"1","preferredName":"Other","longName":"2946060","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"746A8063-D650-3C9D-E040-BB89AD437A9B","latestVersionIndicator":"Yes","beginDate":"2009-09-25","endDate":null,"createdBy":"AHMEDS","dateCreated":"2009-09-25","modifiedBy":"GDEEN","dateModified":"2024-01-19","changeDescription":null,"administrativeNotes":"1/25/23 added alt name for ticket number CADSR0001948 for CCTG cjl.","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F3F96ADF-8CD0-F527-E040-BB89AD436570","beginDate":"2014-03-06","endDate":null,"createdBy":"ZIEGLERK","dateCreated":"2014-03-06","modifiedBy":"ONEDATA","dateModified":"2014-03-06","deletedIndicator":"No"},{"value":"PD1 or PDL1 inhibitor","valueDescription":"PD1 or PDL1 inhibitor","ValueMeaning":{"publicId":"4199898","version":"1","preferredName":"PD1 or PDL1 inhibitor","longName":"4199898","preferredDefinition":"PD1 or PDL1 inhibitor","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F3F96ADF-8CDA-F527-E040-BB89AD436570","latestVersionIndicator":"Yes","beginDate":"2014-03-06","endDate":null,"createdBy":"ZIEGLERK","dateCreated":"2014-03-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F3F96ADF-8CF3-F527-E040-BB89AD436570","beginDate":"2014-03-06","endDate":null,"createdBy":"ZIEGLERK","dateCreated":"2014-03-06","modifiedBy":"ONEDATA","dateModified":"2014-03-06","deletedIndicator":"No"},{"value":"Other oral targeted therapy","valueDescription":"Other oral targeted therapy","ValueMeaning":{"publicId":"4199899","version":"1","preferredName":"Other oral targeted therapy","longName":"4199899","preferredDefinition":"Other oral targeted therapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F3F96ADF-8CFD-F527-E040-BB89AD436570","latestVersionIndicator":"Yes","beginDate":"2014-03-06","endDate":null,"createdBy":"ZIEGLERK","dateCreated":"2014-03-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F3F96ADF-8D16-F527-E040-BB89AD436570","beginDate":"2014-03-06","endDate":null,"createdBy":"ZIEGLERK","dateCreated":"2014-03-06","modifiedBy":"ONEDATA","dateModified":"2014-03-06","deletedIndicator":"No"},{"value":"Other ALK inhibitor","valueDescription":"Other ALK inhibitor","ValueMeaning":{"publicId":"4199900","version":"1","preferredName":"Other ALK inhibitor","longName":"4199900","preferredDefinition":"Other ALK inhibitor","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F3F96ADF-8D20-F527-E040-BB89AD436570","latestVersionIndicator":"Yes","beginDate":"2014-03-06","endDate":null,"createdBy":"ZIEGLERK","dateCreated":"2014-03-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F3F96ADF-8D39-F527-E040-BB89AD436570","beginDate":"2014-03-06","endDate":null,"createdBy":"ZIEGLERK","dateCreated":"2014-03-06","modifiedBy":"ONEDATA","dateModified":"2014-03-06","deletedIndicator":"No"},{"value":"Crizotinib","valueDescription":"Crizotinib","ValueMeaning":{"publicId":"3377031","version":"1","preferredName":"Crizotinib","longName":"3377031","preferredDefinition":"An orally available aminopyridine-based inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) and the c-Met/hepatocyte growth factor receptor (HGFR) with antineoplastic activity. Crizotinib, in an ATP-competitive manner, binds to and inhibits ALK kinase and ALK fusion proteins. In addition, crizotinib inhibits c-Met kinase, and disrupts the c-Met signaling pathway. Altogether, this agent inhibits tumor cell growth. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK dysregulation and gene rearrangements are associated with a series of tumors.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Crizotinib","conceptCode":"C74061","definition":"An orally available aminopyridine-based inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) and the c-Met/hepatocyte growth factor receptor (HGFR) with antineoplastic activity. Crizotinib, in an ATP-competitive manner, binds to and inhibits ALK kinase and ALK fusion proteins. In addition, crizotinib inhibits c-Met kinase, and disrupts the c-Met signaling pathway. Altogether, this agent inhibits tumor cell growth. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK dysregulation and gene rearrangements are associated with a series of tumors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B89EC9E2-49F5-54C4-E040-BB89AD432648","latestVersionIndicator":"Yes","beginDate":"2012-02-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-10","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F3F96ADF-8D43-F527-E040-BB89AD436570","beginDate":"2014-03-06","endDate":null,"createdBy":"ZIEGLERK","dateCreated":"2014-03-06","modifiedBy":"ONEDATA","dateModified":"2014-03-06","deletedIndicator":"No"},{"value":"Other EGFR inhibitor","valueDescription":"Other EGFR inhibitor","ValueMeaning":{"publicId":"3234997","version":"1","preferredName":"Other EGFR inhibitor","longName":"3234997","preferredDefinition":"Other EGFR inhibitor","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A31A92C2-353E-2449-E040-BB89AD4336BB","latestVersionIndicator":"Yes","beginDate":"2011-05-12","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-05-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F3F96ADF-8D4D-F527-E040-BB89AD436570","beginDate":"2014-03-06","endDate":null,"createdBy":"ZIEGLERK","dateCreated":"2014-03-06","modifiedBy":"ONEDATA","dateModified":"2014-03-06","deletedIndicator":"No"},{"value":"Erlotinib or afatinib","valueDescription":"Erlotinib or afatinib","ValueMeaning":{"publicId":"4199901","version":"1","preferredName":"Erlotinib or afatinib","longName":"4199901","preferredDefinition":"Erlotinib or afatinib","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F3F96ADF-8D57-F527-E040-BB89AD436570","latestVersionIndicator":"Yes","beginDate":"2014-03-06","endDate":null,"createdBy":"ZIEGLERK","dateCreated":"2014-03-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F3F96ADF-8D70-F527-E040-BB89AD436570","beginDate":"2014-03-06","endDate":null,"createdBy":"ZIEGLERK","dateCreated":"2014-03-06","modifiedBy":"ONEDATA","dateModified":"2014-03-06","deletedIndicator":"No"},{"value":"Single-agent chemotherapy: other","valueDescription":"Single-agent chemotherapy: other","ValueMeaning":{"publicId":"4199902","version":"1","preferredName":"Single-agent chemotherapy: other","longName":"4199902","preferredDefinition":"Single-agent chemotherapy: other","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F3F96ADF-8D7A-F527-E040-BB89AD436570","latestVersionIndicator":"Yes","beginDate":"2014-03-06","endDate":null,"createdBy":"ZIEGLERK","dateCreated":"2014-03-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F3F96ADF-8D93-F527-E040-BB89AD436570","beginDate":"2014-03-06","endDate":null,"createdBy":"ZIEGLERK","dateCreated":"2014-03-06","modifiedBy":"ONEDATA","dateModified":"2014-03-06","deletedIndicator":"No"},{"value":"Single-agent chemotherapy: taxane","valueDescription":"Single-agent chemotherapy: taxane","ValueMeaning":{"publicId":"4199903","version":"1","preferredName":"Single-agent chemotherapy: taxane","longName":"4199903","preferredDefinition":"Single-agent chemotherapy: taxane","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F3F96ADF-8D9D-F527-E040-BB89AD436570","latestVersionIndicator":"Yes","beginDate":"2014-03-06","endDate":null,"createdBy":"ZIEGLERK","dateCreated":"2014-03-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F3F96ADF-8DB6-F527-E040-BB89AD436570","beginDate":"2014-03-06","endDate":null,"createdBy":"ZIEGLERK","dateCreated":"2014-03-06","modifiedBy":"ONEDATA","dateModified":"2014-03-06","deletedIndicator":"No"},{"value":"Single-agent chemotherapy: pemetrexed","valueDescription":"Single-agent chemotherapy: pemetrexed","ValueMeaning":{"publicId":"4199904","version":"1","preferredName":"Single-agent chemotherapy: pemetrexed","longName":"4199904","preferredDefinition":"Single-agent chemotherapy: pemetrexed","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F3F96ADF-8DC0-F527-E040-BB89AD436570","latestVersionIndicator":"Yes","beginDate":"2014-03-06","endDate":null,"createdBy":"ZIEGLERK","dateCreated":"2014-03-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F3F96ADF-8DD9-F527-E040-BB89AD436570","beginDate":"2014-03-06","endDate":null,"createdBy":"ZIEGLERK","dateCreated":"2014-03-06","modifiedBy":"ONEDATA","dateModified":"2014-03-06","deletedIndicator":"No"},{"value":"Combination chemotherapy: other","valueDescription":"Combination chemotherapy: other","ValueMeaning":{"publicId":"4199905","version":"1","preferredName":"Combination chemotherapy: other","longName":"4199905","preferredDefinition":"Combination chemotherapy: other","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F3F96ADF-8DE3-F527-E040-BB89AD436570","latestVersionIndicator":"Yes","beginDate":"2014-03-06","endDate":null,"createdBy":"ZIEGLERK","dateCreated":"2014-03-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F3F96ADF-8DFC-F527-E040-BB89AD436570","beginDate":"2014-03-06","endDate":null,"createdBy":"ZIEGLERK","dateCreated":"2014-03-06","modifiedBy":"ONEDATA","dateModified":"2014-03-06","deletedIndicator":"No"},{"value":"Combination chemotherapy: taxane-based","valueDescription":"Combination chemotherapy: taxane-based","ValueMeaning":{"publicId":"4199906","version":"1","preferredName":"Combination chemotherapy: taxane-based","longName":"4199906","preferredDefinition":"Combination chemotherapy: taxane-based","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F3F96ADF-8E06-F527-E040-BB89AD436570","latestVersionIndicator":"Yes","beginDate":"2014-03-06","endDate":null,"createdBy":"ZIEGLERK","dateCreated":"2014-03-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F3F96ADF-8E1F-F527-E040-BB89AD436570","beginDate":"2014-03-06","endDate":null,"createdBy":"ZIEGLERK","dateCreated":"2014-03-06","modifiedBy":"ONEDATA","dateModified":"2014-03-06","deletedIndicator":"No"},{"value":"Combination chemotherapy: pemetrexed-based","valueDescription":"Combination chemotherapy: pemetrexed-based","ValueMeaning":{"publicId":"4199907","version":"1","preferredName":"Combination chemotherapy: pemetrexed-based","longName":"4199907","preferredDefinition":"Combination chemotherapy: pemetrexed-based","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F3F96ADF-8E29-F527-E040-BB89AD436570","latestVersionIndicator":"Yes","beginDate":"2014-03-06","endDate":null,"createdBy":"ZIEGLERK","dateCreated":"2014-03-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F3F96ADF-8E42-F527-E040-BB89AD436570","beginDate":"2014-03-06","endDate":null,"createdBy":"ZIEGLERK","dateCreated":"2014-03-06","modifiedBy":"ONEDATA","dateModified":"2014-03-06","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2229718","version":"1","preferredName":"Name","preferredDefinition":"The words or language units by which a thing is known.","longName":"C42614","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Name","conceptCode":"C42614","definition":"The words or language units by which a thing is known.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F6EF4E2B-76AE-72C1-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-05-16","endDate":null,"createdBy":"MAESKEB","dateCreated":"2005-05-16","modifiedBy":"ONEDATA","dateModified":"2005-05-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"Alliance Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F3F96ADF-8CBC-F527-E040-BB89AD436570","latestVersionIndicator":"Yes","beginDate":"2014-03-06","endDate":null,"createdBy":"ZIEGLERK","dateCreated":"2014-03-06","modifiedBy":"ZIEGLERK","dateModified":"2014-04-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[{"name":"LUNGSYSTX","type":"USED_BY","context":"Alliance"}],"ReferenceDocuments":[{"name":"Type of systemic therapy","type":"Preferred Question Text","description":"Type of systemic therapy","url":null,"context":"Alliance"}],"origin":"Alliance Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F3F96ADF-8E4C-F527-E040-BB89AD436570","latestVersionIndicator":"Yes","beginDate":"2014-03-06","endDate":null,"createdBy":"ZIEGLERK","dateCreated":"2014-03-06","modifiedBy":"FORMBUILDER","dateModified":"2014-07-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}